The Company reported net income of $356,000, or $0.04 per basic and diluted common shares for the three months ended May 31, 2025, compared to net income of $656,000, or $0.08 per basic and diluted ...
OLDSMAR, Fla.--(BUSINESS WIRE)-- Cryo-Cell International, Inc. (CCEL) (NYSE American LLC: CCEL) (the “Company”, “Cryo-Cell”), the world’s first private cord blood bank to separate and store stem cells ...
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (“Cryo-Cell”), the world’s first private cord blood bank to separate and store stem cells in 1992, ...
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced ...
The Company reported a net loss of $2.4 million in fiscal 2025 or $0.30 per basic and diluted share, compared to net income of $402,000 in fiscal 2024 or $0.05 per basic and diluted share. Due to ...
Cell International, Inc. (NYSE American LLC: CCEL ) (the "Company"), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ...
Cryo-Cell’s public bank has provided cord blood for more than 700 transplants and operates a cord blood donation site at one of the country’s most prominent hospitals, Cedars–Sinai Hospital in Los ...
OLDSMAR, Fla.--(BUSINESS WIRE)-- Cryo-Cell International, Inc. (CCEL) (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results